This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Finance & Accounting for Bioscience Companies
September 18-19, 2024
Omni Boston Hotel at the SeaportBoston, MA

Tom Shoemaker
Audit Partner at Crowe LLP


Tom Shoemaker is a highly experienced Audit Partner at Crowe LLP, specializing in serving clients in the Life Science Industry. With over two decades of experience in the public accounting industry, Tom has developed a unique understanding of the regulatory requirements faced by the life science companies. He has worked with a diverse range of clients including publicly-traded and privately-held companies, spanning from start-ups to mid-size corporations. In addition to his specialization, Tom has experience working with clients across various other industries including Technology, Media & Telecommunication, Manufacturing & Distribution, and Construction & Real Estate Tom has extensive experience with SEC 1933 and 1934 Act filings, including initial public offerings, secondary offerings, reverse mergers, comfort letters, SEC comment letters, and periodic SEC reporting requirements. He has worked with pharmaceutical companies in the clinical stage through commercialization. He has a deep understanding of the technical accounting complexities associated with debt and equity financings, stock-based compensation, and revenue recognition, among others. By being a member of the American Institute of Certified Public Accountants (AICPA) and a member of the California Institute of Certified Public Accountants (CalCPA), Tom highlights his involvement in the accounting community at both the national and state levels. These memberships provide a network of valuable resources and opportunities to support the accounting profession.

Agenda Sessions

  • Pre-commercial: IPO Readiness and SOX Considerations